509 related articles for article (PubMed ID: 33609416)
21. Adalimumab in treatment-resistant hidradenitis suppurativa following recurrence after extensive affected area excision: a review of biologics therapy.
Samycia M; Brassard A
J Cutan Med Surg; 2013 Oct; 17 Suppl 1():S23-32. PubMed ID: 24144253
[TBL] [Abstract][Full Text] [Related]
22. Biology of Interleukin-17 and Novel Therapies for Hidradenitis Suppurativa.
Sabat R; Gudjonsson JE; Brembilla NC; van Straalen KR; Wolk K
J Interferon Cytokine Res; 2023 Dec; 43(12):544-556. PubMed ID: 37824200
[TBL] [Abstract][Full Text] [Related]
23. Hidradenitis Suppurativa as a Potential Subtype of Autoinflammatory Keratinization Disease.
Nomura T
Front Immunol; 2020; 11():847. PubMed ID: 32508815
[TBL] [Abstract][Full Text] [Related]
24. The use of biologics and JAK inhibitors in the management of moderate to severe Hidradenitis Suppurativa treatment: a scoping review.
Guermazi D; Shah A; Yumeen S; Saliba E
Arch Dermatol Res; 2024 May; 316(6):259. PubMed ID: 38795234
[TBL] [Abstract][Full Text] [Related]
25. Evidence-based approach to the treatment of hidradenitis suppurativa/acne inversa, based on the European guidelines for hidradenitis suppurativa.
Gulliver W; Zouboulis CC; Prens E; Jemec GB; Tzellos T
Rev Endocr Metab Disord; 2016 Sep; 17(3):343-351. PubMed ID: 26831295
[TBL] [Abstract][Full Text] [Related]
26. Elevated levels of tumour necrosis factor (TNF)-α, interleukin (IL)-1β and IL-10 in hidradenitis suppurativa skin: a rationale for targeting TNF-α and IL-1β.
van der Zee HH; de Ruiter L; van den Broecke DG; Dik WA; Laman JD; Prens EP
Br J Dermatol; 2011 Jun; 164(6):1292-8. PubMed ID: 21332464
[TBL] [Abstract][Full Text] [Related]
27. Failure of anti-interleukin-1 therapy in severe hidradenitis suppurativa: a case report.
van der Zee HH; Prens EP
Dermatology; 2013; 226(2):97-100. PubMed ID: 23713053
[TBL] [Abstract][Full Text] [Related]
28. Hidradenitis suppurativa managed with adalimumab.
Yamauchi PS; Mau N
J Drugs Dermatol; 2009 Feb; 8(2):181-3. PubMed ID: 19213236
[TBL] [Abstract][Full Text] [Related]
29. Treatment of hidradenitis suppurativa with brodalumab in biologic treatment failures: experiences from a specialty clinic.
Kearney N; Hughes R; Kirby B
Clin Exp Dermatol; 2023 Jul; 48(7):790-792. PubMed ID: 37017188
[TBL] [Abstract][Full Text] [Related]
30. Coprevalence of Hidradenitis Suppurativa and Psoriasis: Detailed Demographic, Disease Severity and Comorbidity Pattern.
Pinter A; Sarlak M; Zeiner KN; Malisiewicz B; Kaufmann R; Romanelli M; Koenig A; Chiricozzi A
Dermatology; 2021; 237(5):759-768. PubMed ID: 33326954
[TBL] [Abstract][Full Text] [Related]
31. Adalimumab (antitumour necrosis factor-α) treatment of hidradenitis suppurativa ameliorates skin inflammation: an in situ and ex vivo study.
van der Zee HH; Laman JD; de Ruiter L; Dik WA; Prens EP
Br J Dermatol; 2012 Feb; 166(2):298-305. PubMed ID: 22013960
[TBL] [Abstract][Full Text] [Related]
32. Hidradenitis Suppurativa and the Association With Hematological Malignancies.
Sotoodian B; Abbas M; Brassard A
J Cutan Med Surg; 2017; 21(2):158-161. PubMed ID: 27573126
[TBL] [Abstract][Full Text] [Related]
33. Ustekinumab treatment for hidradenitis suppurativa.
Takeda K; Kikuchi K; Kanazawa Y; Yamasaki K; Aiba S
J Dermatol; 2019 Dec; 46(12):1215-1218. PubMed ID: 31638283
[TBL] [Abstract][Full Text] [Related]
34. Twenty-four-week interim analysis from a phase 3 open-label trial of adalimumab in Japanese patients with moderate to severe hidradenitis suppurativa.
Morita A; Takahashi H; Ozawa K; Imafuku S; Nakama T; Takahashi K; Matsuyama T; Okubo Y; Kitamura S; Matsuda N; Zhao Y; Yokoyama M; Hayashi N; Terui T
J Dermatol; 2019 Sep; 46(9):745-751. PubMed ID: 31282051
[TBL] [Abstract][Full Text] [Related]
35. Novel Therapeutic Approaches and Targets for the Treatment of Hidradenitis Suppurativa.
Giuffrida R; Cannavò SP; Coppola M; Guarneri C
Curr Pharm Biotechnol; 2021; 22(1):59-72. PubMed ID: 32368973
[TBL] [Abstract][Full Text] [Related]
36. Paradoxical Hidradenitis Suppurativa during Biologic Therapy, an Emerging Challenge: A Systematic Review.
Ruggiero A; Martora F; Picone V; Marano L; Fabbrocini G; Marasca C
Biomedicines; 2022 Feb; 10(2):. PubMed ID: 35203664
[TBL] [Abstract][Full Text] [Related]
37. A safety review of biologic therapies for the management of hidradenitis suppurativa and unmet needs.
Holcomb ZE; Porter ML; Kimball AB
Expert Opin Drug Saf; 2021 Oct; 20(10):1147-1161. PubMed ID: 33910441
[TBL] [Abstract][Full Text] [Related]
38. LOSS OF EFFICACY OF ADALIMUMAB IN HIDRADENITIS SUPPURATIVA: FOCUS ON ALTERNATIVES.
Tchernev G
Georgian Med News; 2023; (340-341):297-300. PubMed ID: 37805915
[TBL] [Abstract][Full Text] [Related]
39. Pharmacologic interventions for hidradenitis suppurativa: what does the evidence say?
Alhusayen R; Shear NH
Am J Clin Dermatol; 2012 Oct; 13(5):283-91. PubMed ID: 22676319
[TBL] [Abstract][Full Text] [Related]
40. Secukinumab in the treatment of hidradenitis suppurativa.
Snyder CL; Gibson RS; Porter ML; Kimball AB
Immunotherapy; 2023 Dec; 15(17):1449-1457. PubMed ID: 37840286
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]